AQ5-24895-66659
4 vaccinations
1 coded response
10 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 140 / NY
- Registered
- 2021-12-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-10
Dose 1 — Pfizer-BioNTech
-
2021-02-01
Dose 2 — Pfizer-BioNTech
-
2021-11-24
Dose 3 — Pfizer-BioNTech
-
2021-12-16
Registered in v-safe
- 2021-12-16
- 2021-12-22
- 2021-12-29
- 2022-01-05
- 2022-02-24
-
2022-05-27
Survey response — 6 months, dose 3MedDRA: Postpartum state, Pre-eclampsia — Feeling: Good · Be unable to work or attend schoolFree text: Postpartum preeclampsia, three days after deliveryMedDRA releases: 2024-11 · check-in free text available
-
2022-09-12
Dose 4 — Pfizer-BioNTech
- 2022-10-12
- 2022-10-24
- 2022-12-12
- 2023-03-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-10 | Pfizer-BioNTech | No |
| 2 | 2021-02-01 | Pfizer-BioNTech | No |
| 3 | 2021-11-24 | Pfizer-BioNTech | No |
| 4 | 2022-09-12 | Pfizer-BioNTech | No |
Free text
Release 11 — 6 months, dose 3
Symptoms: Postpartum preeclampsia, three days after delivery
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Postpartum state | · | · | ✓ |
| SD | Pre-eclampsia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release